Predictors of Vein Thrombosis at Lower Limb Joints Arthroplasty in Oncologic Patients

Abstract

Purpose of the study was to detect the factors that stipulated risk of vein thrombosis at arthroplasty of lower limb joints in oncologic patients. Retrospective data on 374 patients after hip and knee arthroplasty aa well as after total femur replacement were studied. The following risk factors were studied: age, gender, weight, height, body mass index, preoperative hemoglobin level, tumor morphology, presence of pathologic fracture, use of tranexamic acid, tourniquet application, type of regional anesthesia, intraoperative blood loss, duration of surgical intervention. Statistical analysis was performed using the method of multifactorial logistic regression. Independent risk factor for perioperative vein thrombosis was the age of patient (likelihood ratio χ2=26,6; р=0,000) In patients of 40 years and older the rate of thrombosis was higher as compared to younger ones: 24.4% (31/127) versus 6.1% (15/247); p =0.000; odds ratio 5; 95% confidence interval 2.6 - 9.7. Preoperative risk of vein thrombosis increased not only with patient’s age but in presence of pathologic fracture as well (likelihood ratio χ2 = 29,8; р=0,000) Other studied factors did not increase the rate of thrombosis. In presence of pathologic fracture the possibility of early anticoagulant therapy should be considered. Both prolonged epidural and peripheral nerve blockades can be used at such surgical interventions without risk of vein thrombosis rate increase.

Keywords

vein thrombosis predictors / arthroplasty / hip joint / knee joint

References

[1] Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии. Российские клинические рекомендации. Травматология и ортопедия России. 2012; 1 (63): 1-24.

[2] Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2010; 4 (2): 2-37.

[3] Российские клинические рекомендации по профилактике и лечению венозных тромбоэмболических осложнений у онкологических больных [Электронный ресурс]. Ассоциация флебологов России. Режим доступа: свободный (дата обращения: 31.05.2014). http://www.phlebo-union.ru/db.img/vte_in_oncology_final_04.05.2011.pdf

[4] Приказ МЗ РФ № 233 от 09.06.2003 г. об утверждении отраслевого стандарта ОСТ 91500.11.0007-2003: «Протокол ведения больных. Профилактика тромбоэмболии легочной артерии при хирургических и иных инвазивных вмешательствах».

[5] Johanson N.A., Lachiewicz P.F., Lieberman J.R., Lotke P.A., Parvizi J., Pellegrini V. et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J. Am. Acad. Orthop. Surg. 2009; 17 (3): 183-96.

[6] Mont M.A., Jacobs J.J., Boggio L.N., Bozic K.J., Della Valle C.J., Goodman S.B. et al. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J. Am. Acad. Orthop. Surg. 2011; 19: 768-76.

[7] Guyatt G.H., Akl E.A., Crowther M., Gutterman D.D., Schuünemann H.J. Executive Summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141 (Suppl. 2): 7S-47S.

[8] Anderson M.R., Jeng C.L., Wittig J.C., Rosenblatt M.A. Anesthesia for patients undergoing orthopedic oncologic surgeries. J. Clin. Anest. 2010; 22: 565-72.

[9] Henry D.A., Carless P.A., Moxey A.J., O'Connell D., Stokes B.J., Fergusson D.A., Ker K. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst. Rev. 2011; 3: CD001886.

RIGHTS & PERMISSIONS

Eco-Vector